Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View PCRX insider activity ↗

PCRXPacira BioSciences, Inc.

THE LATEST REPORTED YEAR

The company reported a profit.

$7.03M net income for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$726.41MYear ended December 31, 2025
Profit or loss$7.03MYear ended December 31, 2025
Cash from the business$151.99MYear ended December 31, 2025
Total assets$1.24BAs of June 30, 2026
Total liabilities$572MAs of June 30, 2026
Cash & equivalents$205.88MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$332.43M
2018-12
$418.93M
2019-12
$429.65M
2020-12
$541.53M
2021-12
$666.82M
2022-12
$674.98M
2023-12
$700.97M
2024-12
$726.41M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$726,411,000February 26, 202610-K ↗
January 1, 2024 – December 31, 2024$700,966,000February 26, 202610-K ↗
January 1, 2023 – December 31, 2023$674,978,000February 26, 202610-K ↗
January 1, 2022 – December 31, 2022$666,823,000February 29, 202410-K ↗
January 1, 2021 – December 31, 2021$541,533,000February 29, 202410-K ↗
January 1, 2020 – December 31, 2020$429,647,000February 28, 202310-K ↗
January 1, 2019 – December 31, 2019$418,926,000February 28, 202210-K ↗
January 1, 2018 – December 31, 2018$332,427,000March 1, 202110-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 11, 2026

Response SHA-256: 6affb2af75e06da1c253dbc3d14567743a6ab33921a8ed37b907a1d2ebb9f9da

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.